Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Front Immunol ; 12: 653710, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33912179

RESUMO

Antiseizure medications (ASMs) are frequently implicated in T cell-mediated drug hypersensitivity reactions and cause skin tropic pathologies that range in severity from mild rashes to life-threatening systemic syndromes. During the acute stages of the more severe manifestations of these reactions, drug responsive proinflammatory CD8+ T cells display classical features of Th1 cytokine production (e.g. IFNγ) and cytolysis (e.g. granzyme B, perforin). These T cells may be found locally at the site of pathology (e.g. blister cells/fluid), as well as systemically (e.g. blood, organs). What is less understood are the long-lived immunological effects of the memory T cell pool following T cell-mediated drug hypersensitivity reactions. In this study, we examine the ASM carbamazepine (CBZ) and the CBZ-reactive memory T cell pool in patients who have a history of either Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) from 3-to-20 years following their initial adverse reaction. We show that in vitro drug restimulation of CBZ-reactive CD8+ T cells results in a proinflammatory profile and produces a mainly focused, yet private, T cell receptor (TCR) usage amongst human leukocyte antigen (HLA)-B*15:02-positive SJS or TEN patients. Additionally, we show that expression of these CBZ-reactive TCRs in a reporter cell line, lacking endogenous αßTCR, recapitulates the features of TCR activation reported for ASM-treated T cell lines/clones, providing a useful tool for further functional validations. Finally, we conduct a comprehensive evaluation of the HLA-B*15:02 immunopeptidome following ASM (or a metabolite) treatment of a HLA-B*15:02-positive B-lymphoblastoid cell line (C1R.B*15:02) and minor perturbation of the peptide repertoire. Collectively, this study shows that the CBZ-reactive T cells characterized require both the drug and HLA-B*15:02 for activation and that reactivation of memory T cells from blood results in a focused private TCR profile in patients with resolved disease.


Assuntos
Anticonvulsivantes/efeitos adversos , Linfócitos T CD8-Positivos/imunologia , Carbamazepina/efeitos adversos , Seleção Clonal Mediada por Antígeno/efeitos dos fármacos , Síndrome de Stevens-Johnson/imunologia , Linfócitos T CD8-Positivos/efeitos dos fármacos , Linfócitos T CD8-Positivos/metabolismo , Estudos de Casos e Controles , Linhagem Celular Tumoral , Seleção Clonal Mediada por Antígeno/genética , Feminino , Antígeno HLA-B15/análise , Antígeno HLA-B15/metabolismo , Voluntários Saudáveis , Humanos , Memória Imunológica/efeitos dos fármacos , Masculino , Peptídeos/análise , Peptídeos/metabolismo , Cultura Primária de Células , Proteômica , Receptores de Antígenos de Linfócitos T/genética , Receptores de Antígenos de Linfócitos T/metabolismo , Síndrome de Stevens-Johnson/sangue
3.
Blood ; 121(1): 107-17, 2013 Jan 03.
Artigo em Inglês | MEDLINE | ID: mdl-23043071

RESUMO

The primary consequence of positive selection is to render thymocytes responsive to cytokines and chemokines expressed in the thymic medulla. In the present study, our main objective was to discover which cytokines could support the differentiation of positively selected thymocytes. To this end, we have developed an in vitro model suitable for high-throughput analyses of positive selection and CD8 T-cell differentiation. The model involves coculture of TCR(hi)CD5(int)CD69(-) double-positive (DP) thymocytes with peptide-pulsed OP9 cells and γc-cytokines. We report that IL-4, IL-7, and IL-21 have nonredundant effects on positively selected DP thymocytes. IL-7 signaling phosphorylates STAT5 and ERK; induces Foxo1, Klf2, and S1pr1; and supports the differentiation of classic CD8 T cells. IL-4 activates STAT6 and ERK and supports the differentiation of CD8(int)PD-L1(hi)CD44(hi)EOMES(+) innate CD8 T cells. IL-21 is produced by thymic epithelial cells and the IL-21 receptor-α is strongly induced on DP thymocytes undergoing positive selection. IL-21 signaling phosphorylates STAT3 and STAT5, but not ERK, and does not support CD8 T-cell differentiation. However, IL-21 has a unique ability to up-regulate BCL-6, expand DP thymocytes undergoing positive selection, and increase the production of mature T cells. Our data suggest that injection of recombinant IL-21 might enhance thymic output in subjects with age- or disease-related thymic atrophy.


Assuntos
Seleção Clonal Mediada por Antígeno/efeitos dos fármacos , Citocinas/fisiologia , Subunidade gama Comum de Receptores de Interleucina/efeitos dos fármacos , Linfopoese/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacos , Linfócitos T/citologia , Timócitos/citologia , Timo/citologia , Animais , Atrofia , Células Cultivadas/citologia , Células Cultivadas/efeitos dos fármacos , Técnicas de Cocultura , Citocinas/farmacologia , Células Epiteliais/metabolismo , Ensaios de Triagem em Larga Escala , Imunocompetência/efeitos dos fármacos , Subunidade gama Comum de Receptores de Interleucina/fisiologia , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Fosforilação , Processamento de Proteína Pós-Traducional , Proteínas Recombinantes/farmacologia , Fatores de Transcrição STAT/metabolismo , Organismos Livres de Patógenos Específicos , Timo/efeitos dos fármacos , Timo/imunologia , Timo/patologia
4.
Int Immunol ; 24(12): 783-91, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22949567

RESUMO

Thymic epithelial cells (TECs) play a central role in T-cell development by presenting self-antigens on MHC proteins. Double-positive (DP) thymocytes that fail to interact with TEC via their TCR die by 'Death by Neglect'. We demonstrated a role for TEC-derived glucocorticoids (GCs) in this process. In a previous study, we used an in vitro system recapitulating Death by Neglect, to demonstrate the involvement of nitric oxide (NO) and inducible NO synthase (iNOS) in this process. In this study, we show that NO synergizes with GCs to induce apoptosis of DP thymocytes in a fetal thymic organ culture. Also, DP thymocytes from iNOS⁻/⁻ mice are less sensitive to GC-induced apoptosis. Furthermore, the number of DP thymocytes in iNOS⁻/⁻ mice is higher than in wild-type mice, suggesting a role for NO in Death by Neglect. This phenomenon effects T-cell function profoundly: iNOS⁻/⁻ T cells do not respond to TCR-mediated activation signals, measured by up-regulation of CD69, IL-2R and IFNγ secretion. This failure to activate is a result of TCR incompetence because iNO⁻/⁻ T cells respond to TCR-independent stimuli (phorbol myristate acetate and calcium ionophore). This study suggests that NO and GCs synergize to execute TEC-induced death of DP thymocytes.


Assuntos
Apoptose , Células Epiteliais/efeitos dos fármacos , Glucocorticoides/farmacologia , Óxido Nítrico/metabolismo , Células Precursoras de Linfócitos T/efeitos dos fármacos , Linfócitos T/efeitos dos fármacos , Timo/imunologia , Animais , Apresentação de Antígeno/efeitos dos fármacos , Autoantígenos/imunologia , Antígenos CD4/metabolismo , Antígenos CD8/metabolismo , Células Cultivadas , Seleção Clonal Mediada por Antígeno/efeitos dos fármacos , Células Epiteliais/imunologia , Humanos , Interferon gama/metabolismo , Ativação Linfocitária/efeitos dos fármacos , Ativação Linfocitária/imunologia , Camundongos , Camundongos Knockout , Óxido Nítrico Sintase Tipo II/genética , Células Precursoras de Linfócitos T/imunologia , Receptores de Antígenos de Linfócitos T , Receptores de Interleucina-2/genética , Receptores de Interleucina-2/metabolismo , Linfócitos T/imunologia
5.
Trends Immunol ; 32(8): 388-94, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21752714

RESUMO

B cell activating factor (BAFF) is a crucial survival factor for transitional and mature B cells, and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF inhibitor, belimumab, is the first new drug in 50 years to be approved for the treatment of SLE. However, the mechanism of action of this drug is not entirely clear. In this review we will focus on the role of the BAFF-APRIL signaling pathway in the selection of autoreactive B cells, and discuss whether altered selection is the mechanism for the therapeutic efficacy of BAFF inhibition in SLE.


Assuntos
Fator Ativador de Células B/imunologia , Linfócitos B/imunologia , Seleção Clonal Mediada por Antígeno , Lúpus Eritematoso Sistêmico/imunologia , Membro 13 da Superfamília de Ligantes de Fatores de Necrose Tumoral/imunologia , Animais , Anticorpos Monoclonais/farmacologia , Anticorpos Monoclonais Humanizados , Autoimunidade/efeitos dos fármacos , Linfócitos B/efeitos dos fármacos , Seleção Clonal Mediada por Antígeno/efeitos dos fármacos , Humanos , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...